UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)
SOLTA MEDICAL, INC.
(Name of Subject Company (Issuer))
Sapphire Subsidiary Corp.
a wholly owned subsidiary of
Valeant Pharmaceuticals International
a wholly owned subsidiary of
Valeant Pharmaceuticals International, Inc.
(Names of Filing Persons (Offerors))
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class Of Securities)
83438K103
(CUSIP Number of Class of Securities)
Robert Chai-Onn
Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development
Valeant Pharmaceuticals International, Inc.
2150 St. Elzéar Blvd. West
Laval, Quebec
Canada, H7L 4A8
(949) 461-6000
(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)
With copies to:
Stephen F. Arcano
Marie L. Gibson
Skadden, Arps, Slate, Meagher & Flom LLP
4 Times Square
New York, NY 10036
(212) 735-3000
CALCULATION OF FILING FEE
Transaction Valuation(1) | Amount Of Filing Fee(2) | |
$267,559,392.68 |
$34,461.65 | |
|
(1) | The transaction valuation is an estimate calculated solely for purposes of determining the amount of the filing fee. The transaction valuation was determined by multiplying (x) $2.92 (i.e., the tender offer price) by (y) the sum of (a) 83,861,129, the number of shares of common stock issued and outstanding (including 2,673,559 shares subject to restricted stock awards), plus (b) 3,181,829, the number of shares of common stock issuable upon the exercise of outstanding stock options, plus (c) 4,586,971, the number of shares of common stock issuable upon the exercise of outstanding warrants. The foregoing share figures have been provided by the issuer to the offerors and are as of December 12, 2013, the most recent practicable date. |
(2) | The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for Fiscal Year 2014, issued August 30, 2013, by multiplying the transaction value by 0.00012880. |
x | Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
Amount Previously Paid: $34,461.65 | Filing Party: Sapphire Subsidiary Corp., Valeant Pharmaceuticals International and Valeant Pharmaceuticals International, Inc. | |
Form or Registration No.: Schedule TO-T; Schedule TO/A | Date Filed: December 23, 2013; January 13, 2014 |
¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
x | third-party tender offer subject to Rule 14d-1. |
¨ | issuer tender offer subject to Rule 13e-4. |
¨ | going-private transaction subject to Rule 13e-3. |
¨ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
¨ | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) |
¨ | Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) |
This Amendment No. 2 (Amendment No. 2) amends and supplements the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission (the SEC) on December 23, 2013, and amended on January 13, 2014 (the Schedule TO) and relates to the offer of Sapphire Subsidiary Corp., a Delaware corporation (the Purchaser), to purchase all outstanding shares of common stock, par value $0.001 per share (each a Share), of Solta Medical, Inc., a Delaware corporation (Solta or the Company), at a price of $2.92 per Share, net to the seller in cash, without interest (the Offer Price), less any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 23, 2013 (as it may be amended or supplemented, the Offer to Purchase) and in the related Letter of Transmittal (as it may be amended or supplemented, the Letter of Transmittal and, together with the Offer to Purchase, the Offer), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. The Purchaser is a wholly owned subsidiary of Valeant Pharmaceuticals International, a Delaware corporation (VPI), which is a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., a Canadian corporation (Valeant). This Amendment No. 2 is being filed on behalf of VPI, Valeant and the Purchaser.
All the information set forth in the Offer to Purchase, to the extent incorporated by reference therein, is hereby amended and supplemented as set forth below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Offer to Purchase.
ITEM 11. | ADDITIONAL INFORMATION |
The Offer to Purchase and Items 1 through 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as set forth below.
The section of the Offer to Purchase entitled Antitrust in Section 16 of the Offer to Purchase entitled Certain Legal Matters; Regulatory Approvals is hereby amended and supplemented by deleting the second paragraph and replacing it in its entirety with the following:
Under the HSR Act, the purchase of Shares in the Offer may not be completed until the expiration of a 15-calendar-day waiting period following the filing of certain required information and documentary material concerning the Offer (and the Merger) with the FTC and the Antitrust Division, unless the waiting period is earlier terminated by the FTC and the Antitrust Division. The applicable waiting period under the HSR Act with respect to the purchase of Shares in the Offer and the Merger expired at 11:59 P.M., New York City time, on January 14, 2014. Accordingly, the condition of the Offer relating to the expiration or termination of the HSR Act waiting period has been satisfied. On January 15, 2014, Valeant issued a press release announcing the expiration of the waiting period under the HSR Act. The full text of the press release is attached as Exhibit (a)(5)(C) to the Schedule TO and is incorporated herein by reference.
ITEM 12. | EXHIBITS |
Item 12 of the Schedule TO is hereby amended and supplemented to add the following exhibit:
(a)(5)(C) Press Release issued by Valeant Pharmaceuticals International, Inc. on January 15, 2014.
2
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: January 15, 2014
SAPPHIRE SUBSIDIARY CORP. | ||||
By: | /s/ Robert Chai-Onn | |||
Name: | Robert Chai-Onn | |||
Title: | Secretary | |||
VALEANT PHARMACEUTICALS INTERNATIONAL | ||||
By: | /s/ Robert Chai-Onn | |||
Name: | Robert Chai-Onn | |||
Title: | Executive Vice President, General Counsel and Corporate Secretary | |||
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. | ||||
By: | /s/ Robert Chai-Onn | |||
Name: | Robert Chai-Onn | |||
Title: | Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development |
3
EXHIBIT INDEX
(a)(1)(A) | Offer to Purchase, dated December 23, 2013.* | |
(a)(1)(B) | Form of Letter of Transmittal.* | |
(a)(1)(C) | Form of Notice of Guaranteed Delivery.* | |
(a)(1)(D) | Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* | |
(a)(1)(E) | Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.* | |
(a)(1)(F) | Form of Internal Revenue Service Form W-9 (Request for Taxpayer Identification Number and Certification), including instructions for completing the form.* | |
(a)(2) | Not applicable. | |
(a)(3) | Not applicable. | |
(a)(4) | Not applicable. | |
(a)(5)(A) | Joint Press Release issued by Valeant and Solta on December 16, 2013, originally filed as Exhibit (a)(5)(A) to the Tender Offer Statement on Schedule TOC filed by the Purchaser, VPI and Valeant with the Securities and Exchange Commission on December 17, 2013, which is incorporated by reference herein. | |
(a)(5)(B) | Form of Summary Advertisement.* | |
(a)(5)(C) | Press Release issued by Valeant Pharmaceuticals International, Inc. on January 15, 2014. | |
(b)(1) | Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012, among Valeant, certain subsidiaries of Valeant as Guarantors, each of the lenders named therein, J.P. Morgan Securities LLC, Goldman Sachs Lending Partners LLC (GSLP) and Morgan Stanley Senior Funding, Inc. (Morgan Stanley), as Joint Lead Arrangers and Joint Bookrunners, JPMorgan Chase Bank, N.A. (JPMorgan) and Morgan Stanley, as Co-Syndication Agents, JPMorgan, as Issuing Bank, GSLP, as Administrative Agent and Collateral Agent, and the other agents party thereto (the Third Amended and Restated Credit and Guaranty Agreement of Valeant Pharmaceuticals International, Inc.), originally filed as Exhibit 10.1 to Valeants Current Report on Form 8-K filed on February 17, 2012, which is incorporated by reference herein. | |
(b)(2) | Amendment No. 1, dated March 6, 2012, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.1 to Valeants Quarterly Report on Form 10-Q filed on November 5, 2012, which is incorporated by reference herein. | |
(b)(3) | Amendment No. 2, dated September 10, 2012, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.2 to Valeants Quarterly Report on Form 10-Q filed on November 5, 2012, which is incorporated by reference herein. | |
(b)(4) | Amendment No. 3, dated January 24, 2013, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.25 to Valeants Annual Report on Form 10-K filed on February 28, 2012, which is incorporated by reference herein. |
4
(b)(5) | Amendment No. 4, dated February 21, 2013, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.26 to Valeants Annual Report on Form 10-K filed on February 28, 2012, which is incorporated by reference herein. | |
(b)(6) | Amendment No. 5, dated as of June 6, 2013, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.3 to Valeants Quarterly Report on Form 10-Q filed on August 8, 2013, which is incorporated by reference herein. | |
(b)(7) | Amendment No. 6, dated June 26, 2013, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.4 to Valeants Quarterly Report on Form 10-Q filed on August 8, 2013, which is incorporated by reference herein. | |
(b)(8) | Amendment No. 7, dated September 17, 2013, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.3 to Valeants Quarterly Report on Form 10-Q filed on November 1, 2013, which is incorporated by reference herein. | |
(b)(9) | Joinder Agreement, dated June 14, 2012, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.1 to Valeants Current Report on Form 8-K filed on June 15, 2012, which is incorporated by reference herein. | |
(b)(10) | Joinder Agreement, dated July 9, 2012, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.2 to Valeants Quarterly Report on Form 10-Q filed on August 3, 2012, which is incorporated by reference herein. | |
(b)(11) | Joinder Agreement, dated as of September 11, 2012, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.3 to Valeants Quarterly Report on Form 10-Q filed on November 5, 2012, which is incorporated by reference herein. | |
(b)(12) | Joinder Agreement, dated as of October 2, 2012, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.1 to Valeants Current Report on Form 8-K filed on October 9, 2012, which is incorporated by reference herein. | |
(b)(13) | Joinder Agreement, dated as of December 11, 2012, to the Third Amended and Restated Credit and Guaranty Agreement of Valeant, originally filed as Exhibit 10.31 to Valeants Annual Report on Form 10-K filed on February 28, 2012, which is incorporated by reference herein. | |
(d)(1) | Agreement and Plan of Merger, dated as of December 15, 2013, by and among VPI, the Purchaser, Valeant and Solta, originally filed as Exhibit 2.1 to Soltas Current Report on Form 8-K filed with the Securities and Exchange Commission on December 17, 2013, which is incorporated by reference herein. | |
(d)(2) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and Harold L. Covert.* | |
(d)(3) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and H. Daniel Ferrari.* | |
(d)(4) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and John Glenn.* | |
(d)(5) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and Linda Graebner.* |
5
(e)(6) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and David Holthe.* | |
(d)(7) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and Inlign CP III, LLC.* | |
(d)(8) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and Cathy L. McCarthy.* | |
(d)(9) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and Jeff Nardoci.* | |
(d)(10) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and Mark M. Sieczkarek.* | |
(d)(11) | Tender Agreement, dated as of December 15, 2013, by and among VPI, the Purchaser and Eric Stang.* | |
(d)(12) | Confidentiality Agreement, dated as of July 7, 2012, between Valeant and Solta.* | |
(d)(13) | Extension of Confidentiality Agreement, dated as of October 31, 2013, between Valeant and Solta.* | |
(g) | Not applicable. | |
(h) | Not applicable. |
* | Previously filed with the Tender Offer Statement on Schedule TO filed by the Purchaser, VPI and Valeant with the Securities and Exchange Commission on December 23, 2013. |
6
Exhibit (a)(5)(C)
International Headquarters
2150 St. Elzéar Blvd. West
Laval, Quebec H7L 4A8
Phone: 514.744.6792
Fax: 514.744.6272
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
VALEANT PHARMACEUTICALS ANNOUNCES RECEIPT OF ANTITRUST CLEARANCE
FOR ITS PREVIOUSLY ANNOUNCED ACQUISITION OF SOLTA MEDICAL, INC.
Laval, Quebec January 15, 2014 Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. (Purchaser), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) (Solta) at a price of $2.92 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Solta expired at 11:59 p.m., New York City time on January 14, 2014. The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Forward-Looking Statements
This press release may contain forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Solta and expected timing of the transaction. Because these statements reflect Valeants current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeants business and/or Soltas business will be adversely impacted during the pendency of the acquisition; the risk that the operations of the two companies will not be integrated successfully; and other risks and uncertainties, including those detailed from time to time in the companies periodic reports filed with the Securities and Exchange Commission (SEC) and in the case of Valeant, the Canadian Securities Administrators (CSA), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, which have been filed with the SEC and in the case of Valeant, the CSA. The forward-looking statements in this press release are qualified by these risk factors. The companies assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Additional Information and Where to Find It
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Solta. Valeant filed a Tender Offer Statement on Schedule TO with the SEC on December 23, 2013. Solta filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer on December 23, 2013. Stockholders of Solta are urged to read the tender offer materials (including the Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as amended (to the extent applicable), because they contain important information which should be read carefully before any decision is made with respect to the tender offer. The Offer to
Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, have been made available to all stockholders of Solta at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement are available to all stockholders of Solta free of charge at the website maintained by the SEC at www.sec.gov. In addition, the tender offer statement and other documents that Valeant files with the SEC are and will be made available to all stockholders of Solta free of charge at www.valeant.com. The Solicitation/Recommendation Statement and the other documents filed by Solta with the SEC are, and will be, made available to all stockholders of Solta free of charge at www.Solta.com.
###